Despite rapid progress, important gaps and controversies remain regarding the precise targets of ALKBH5 in distinct tumor types and immune cell lineages, its bidirectional effects (pro-immunogenic versus immunosuppressive), and its feasibility as a predictive biomarker or therapeutic target in clinical immunotherapy. This evidence concerns the gene ALKBH5 and neoplasm.